Business
Adimab Reports Strong Partnering Year for 2025
Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"– 23 Overall Partnerships in 2025 – – 75 New Programs Added in 2025 – – 50 Milestones Achieved in 2025 – – Generated More Than 650 Total Therapeutic Programs to Date –","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"LEBANON, N.H., Jan. 12, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.","length":357,"tagName":"p"},{"type":"image","alt":"Adimab Logo CMYK","displaySize":"","headline":null,"caption":"Adimab Logo CMYK","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":120,"url":"https://media.zenfs.com/en/prnewswire.com/c0c3400c1b3d3f330f078e841f4163b5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yjkq.AF4jva6vw81Gv8HNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c0c3400c1b3d3f330f078e841f4163b5","width":400,"height":120}},"href":"https://mma.prnewswire.com/media/2859703/Adimab_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Since 2009, Adimab has partnered with over 140 companies to discover therapeutic drug candidates. New alliances for 2025 include collaborations with Central Therapeutics, Enara Bio, Onco3R, Roivant, Variant Bio, and Triptych, among others. In addition, Adimab expanded its collaborations with 12 partners, including Alnylam, 3T Biosciences, Compugen, Cullinan Therapeutics, Lilly, Regeneron, RedRidge, and Therini, among others.","length":428,"tagName":"p"},{"type":"text","content":"In 2025, Adimab and its partners initiated discovery on 75 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to more than 650. Many partners retain the contractual rights to initiate additional royalty-bearing programs with Adimab in the future.","length":285,"tagName":"p"},{"type":"text","content":""We continue to distinguish ourselves by providing solutions for our partners that others cannot," said Guy Van Meter, Chief Business Officer of Adimab. "Our offerings in the multispecific space, from plug-and-play T cell engagers to heterodimerization solutions enabling ...